Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 14 July 2006
Lentivector licensing agreement signed
Oxford BioMedica has signed its seventh licence agreement for its LentiVector technology with a Fortune 500 global biopharmaceutical company
The agreement provides the licensee with use of the company's proprietary LentiVector gene delivery system for research activities Oxford BioMedica will receive an upfront licence payment and an annual maintenance fee
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
Oxford BioMedica's lentivirus-based gene delivery technology, known as LentiVector, is one of the most powerful technologies for the delivery of genes to a wide range of cell and tissue types.
The LentiVector technology has applications both in therapeutic products and as a drug discovery tool for target validation and the creation of targeted disease models.
Oxford BioMedica has a comprehensive portfolio of US and European patents that cover the technology.
The Company has an active licensing programme providing access to its LentiVector technology on a non-exclusive basis primarily.
Licensees and partners include Biogen Idec, Merck, Pfizer, and Viragen.
Oxford BioMedica recently entered a strategic alliance with Sigma-Aldrich for commercialisation of the LentiVector technology for the research and reagents market.
Commenting on the news Oxford BioMedica's senior vice president commercial development, Peter Nolan, said: "We are delighted to have secured our seventh licensee for the LentiVector gene delivery technology.
"The pharmaceutical and biotechnology industry increasingly recognises our gene delivery technology as the system of choice in research and drug discovery, which is reflected by the quality and growing number of licensees".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
